Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225550 | 0.80 | — | — | |
| SCHEMBL9245120 | 0.79 | — | — | |
| SCHEMBL10576834 | 0.79 | USP2 (0.32) | CYP17A1 | |
| SCHEMBL1040058 | 0.79 | USP2 (0.30) | — | |
| SCHEMBL2425760 | 0.78 | — | — | |
| SCHEMBL2455721 | 0.77 | UGT2B7 (0.33) | — | |
| SCHEMBL2425296 | 0.77 | LMNA (0.30) | — | |
| SCHEMBL2426317 | 0.77 | UGT2B7 (0.33) | — | |
| SCHEMBL11725542 | 0.77 | NR1H3 (0.33) | — | |
| SCHEMBL2184333 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | claimed |
| EP-2268599-B1 | Derivatives of campholenic aldehyde | GIVAUDAN SA (CH) | 2011-09-21 | — | — | EP | claimed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | claimed |
| EP-2268599-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2011-01-05 | — | — | EP | claimed |
| US-20100331427-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-30 | — | — | US | claimed |
| US-20100322889-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-23 | — | — | US | claimed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | claimed |
| WO-2009100555-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | claimed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | claimed |
| EP-2074080-B1 | 2, 3, 3 -TRIMETHYLCYCLOPENT-3 -ENECARBALDEHYDE DERIVATIVES USEFUL AS ODORANTS | GIVAUDAN SA (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2268599-B1 | Derivatives of campholenic aldehyde | GIVAUDAN SA (CH) | 2011-09-21 | — | — | EP | disclosed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20110166239-A9 | 2,3,3-Trimethylcyclopent-3-Enecarbaldehyde Derivatives Useful as Odorants | GIVAUDAN SA (CH) | 2011-07-07 | — | — | US | disclosed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100105782-A1 | 2,3,3-Trimethylcyclopent-3-Enecarbaldehyde Derivatives Useful as Odorants | GIVAUDAN SA (CH) | 2010-04-29 | — | — | US | disclosed |
| WO-2009100555-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | disclosed |
| EP-2074080-A1 | 2, 3, 3 -TRIMETHYLCYCLOPENT-3 -ENECARBALDEHYDE DERIVATIVES USEFUL AS ODORANTS | Givaudan SA (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046239-A1 | 2, 3, 3 -TRIMETHYLCYCLOPENT-3 -ENECARBALDEHYDE DERIVATIVES USEFUL AS ODORANTS | GIVAUDAN SA (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331427-A1 | Organic Compounds | C9, C5, CBR3 | CYP17A1 734/4885 |
| US-20100322889-A1 | Organic Compounds | CBR1, CBR3, CYP1B1 | CYP17A1 91/4885 |
| US-20100105782-A1 | 2,3,3-Trimethylcyclopent-3-Enecarbaldehyde Derivatives Useful as Odorants | CBR3, TAS2R5, TAS2R3 | CYP17A1 2209/4885 |
| US-20110166239-A9 | 2,3,3-Trimethylcyclopent-3-Enecarbaldehyde Derivatives Useful as Odorants | CBR3, TAS2R5, TAS2R3 | CYP17A1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.